Loading organizations...
Key people at Cisiv Ltd.
Based in New Malden, England, Cisiv Ltd provides software-as-a-service platforms for data collection, management, and analysis in clinical research and pharmaceutical development. The company specializes in electronic data capture, eConsent, and survey tools designed for late-phase research, observational studies, and post-approval safety registries. Operating with approximately 76 employees, the enterprise generates an estimated $9 million in annual revenue and maintains current assets of £1.7 million. To support the expansion of its Baseline Plus platform across the life sciences sector, the firm secured $2 million in total venture capital funding from institutional investors including Gresham House Ventures and Albion Ventures. These technological solutions are primarily utilized by pharmaceutical companies, contract research organizations, and academic institutions to manage and analyze real-world drug trial data. Cisiv Ltd was founded in 1995 by Dominic Farmer and Ruth Whittaker.
Key people at Cisiv Ltd.
Cisiv Ltd is a UK-based technology company specializing in software solutions for data collection and analysis in the life sciences sector, particularly focused on late phase and real-world research. Its flagship platform, Baseline Plus, supports electronic data capture, eConsent, and surveys for various study types including observational studies, post-approval safety studies, and registries. Cisiv serves a broad client base including biotech, pharmaceutical companies, MedTech firms, contract research organizations, patient advocacy groups, and academic institutions. The company aims to facilitate efficient, accurate real-world data collection without adding burden to patients or healthcare practitioners, supporting better clinical development outcomes[1][3].
Founded in 1995 and originally named Interactive Educational Systems Limited until 2009, Cisiv has evolved over nearly three decades to become a pioneer in real-world data technology. Headquartered in New Malden, Greater London, the company has grown its expertise in late phase research technology, adapting its offerings to meet the complex needs of pharmaceutical and medical device research. The founding team’s background is not explicitly detailed in available sources, but the company’s long-standing presence and evolution reflect a sustained focus on innovation in clinical data management[1][2][4].
Cisiv operates at the intersection of digital health and clinical research, riding the growing trend of leveraging real-world data to complement traditional clinical trials. The timing is critical as regulatory agencies and healthcare stakeholders increasingly recognize the value of real-world evidence for drug safety, effectiveness, and post-market surveillance. Market forces such as the rising complexity of clinical studies, demand for patient-centric approaches, and digital transformation in healthcare favor Cisiv’s technology-driven solutions. By enabling efficient data capture and analysis, Cisiv influences the broader ecosystem by accelerating late phase research and supporting evidence generation that informs regulatory and clinical decision-making[1][3].
Looking ahead, Cisiv is well-positioned to capitalize on the expanding role of real-world data in drug development and medical device evaluation. Trends such as personalized medicine, decentralized trials, and increased regulatory emphasis on real-world evidence will likely shape its growth trajectory. Continued innovation in platform capabilities and expansion of support services could enhance its competitive edge. As the life sciences sector increasingly integrates digital tools, Cisiv’s influence may grow, helping to streamline late phase research and improve patient outcomes through better data insights[1][3].
